Literature DB >> 6290229

Elevated liver enzymes in serum during suloctidil treatment.

J A Schouten, R F Westerman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290229     DOI: 10.1007/bf00609631

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Suloctidil: a novel inhibitor of platelet aggregation in human beings.

Authors:  G de Gaetano; G Miragliotta; R Roncucci; J Lansen; G Lambelin
Journal:  Thromb Res       Date:  1976-03       Impact factor: 3.944

2.  Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole.

Authors:  V Gurewich; B Lipinski
Journal:  Thromb Res       Date:  1976-08       Impact factor: 3.944

3.  Controlled trial of suloctidil in intermittent claudication.

Authors:  R Verhaeghe; A Van Hoof; G Beyens
Journal:  J Cardiovasc Pharmacol       Date:  1981 Mar-Apr       Impact factor: 3.105

  3 in total
  2 in total

1.  Suloctidil hepatitis: a case presentation.

Authors:  C P Kelly; R E England; G S McDonald; D G Weir
Journal:  Ir J Med Sci       Date:  1987-10       Impact factor: 1.568

2.  Effect of suloctidil on rat liver.

Authors:  D Thines-Sempoux; C Bovy-Kesler; E Debruyne; J Roba
Journal:  Arch Toxicol       Date:  1986-07       Impact factor: 5.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.